Welcome to our dedicated page for Kineta SEC filings (Ticker: KA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with Kineta, Inc. (historically Nasdaq: KA and later trading as KANT on OTC Pink) provide a detailed regulatory record of its activities as a clinical-stage biotechnology company and document its transition through a merger with TuHURA Biosciences, Inc. and subsequent deregistration. These filings are a key source for understanding Kineta’s immuno-oncology programs, corporate actions, and ultimate change in status.
For investors and researchers, periodic and current reports historically described Kineta’s focus on developing next-generation immunotherapies in oncology that address cancer immune resistance, including its lead VISTA blocking immunotherapy KVA12123 in the Phase 1/2 VISTA-101 trial for advanced solid tumors. Company disclosures summarized interim clinical data, safety and tolerability observations, and biomarker findings, as well as the impact of corporate restructuring and financing constraints on trial enrollment and operations.
Later filings center on strategic transactions and listing status. An 8-K dated June 24, 2025 reports that on June 23, 2025, Kineta stockholders approved the Agreement and Plan of Merger with TuHURA Biosciences, Hura Merger Sub I, Inc., and Hura Merger Sub II, LLC at a Special Meeting of Stockholders. The filing outlines the proposals presented to stockholders and the voting results, referencing a definitive joint proxy statement/prospectus that provides additional detail on the mergers.
A Form 15 (15-12G) filed on July 2, 2025 is particularly important for understanding Kineta’s current status. Submitted by Kineta, LLC as successor by merger to Kineta, Inc., it certifies the termination of registration of Kineta’s common stock under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of reporting obligations under Sections 13 and 15(d). The explanatory note states that effective June 30, 2025, Merger Sub I merged with and into Kineta, Inc., and the surviving corporation then merged with and into Merger Sub II, which survived as a wholly owned subsidiary of TuHURA under the name Kineta, LLC. The Form 15 lists one holder of record as of the certification date.
Collectively, Kineta’s SEC filings trace the company’s path from a publicly traded clinical-stage immuno-oncology issuer, through restructuring and strategic review, to its combination with TuHURA and deregistration. On a filings platform, users can consult these documents to analyze the terms of the mergers, the rationale for corporate actions, and the regulatory steps that concluded with Kineta, LLC operating as a wholly owned subsidiary of TuHURA.
Kineta Director Kimberlee C. Drapkin reported multiple securities transactions on Form 4, detailing changes in beneficial ownership on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share on June 23
- Disposed of 4,706 common shares at $0.26 per share through tax withholding (Form F)
- Received 6,000 new shares as an award on June 25 at $0 cost
The transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. Per the Optionholder Treatment Agreement dated June 16, 2025, and merger agreement dated December 11, 2024 (amended May 5, 2025), the reporting person's options under the 2022 Equity Incentive Plan became fully vested. Following all transactions, Drapkin directly owns 13,794 common shares with no remaining stock options.
Director Richard Peters of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share on June 23
- Disposed of 4,706 shares at $0.26 per share through share withholding (F code)
- Received 6,000 shares as a new grant on June 25 at $0 cost
The transactions were part of a broader corporate event involving a merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and following stockholder approval on June 23, 2025, Peters' options under the 2022 Equity Incentive Plan became fully vested.
Following these transactions, Peters directly owns 101,891 shares of Kineta common stock. The option exercise eliminated his remaining derivative securities position.
Director Marion R. Foote of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F code)
- Received 6,000 shares as new grant at $0 cost
These transactions were part of changes related to the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and following stockholder approval on June 23, 2025, the director's options under the 2022 Equity Incentive Plan became fully vested.
Following all transactions, Foote directly owns 165,156 shares of Kineta common stock. The exercised stock options, which had an expiration date of September 3, 2034, have been fully utilized, leaving a balance of 0 derivative securities.
Director Scott J. Dylla of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F code)
- Received 6,000 new shares as a grant on June 25 at $0 cost
These transactions occurred in connection with the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and the merger agreement from December 11, 2024 (amended May 5, 2025), Dylla's options under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Following all transactions, Dylla directly owns 17,794 shares and retains 12,500 stock options exercisable until September 2034.
Director David Arkowitz of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share through conversion (M)
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F)
- Received 6,000 new shares as an award (A) at $0
These transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. The merger agreement triggered full vesting of options granted under the 2022 Equity Incentive Plan. Following all transactions, Arkowitz directly owns 18,141 shares of common stock.
The transactions reflect significant insider activity coinciding with the company's merger approval, with the director both exercising options and receiving new equity compensation.
Craig W. Philips, President and Secretary of Kineta, reported multiple securities transactions on June 23-25, 2025:
- Exercised 225,000 stock options at $0.36 per share on June 23
- Disposed of 47,647 shares at $0.26 per share through tax withholding (Form F)
- Acquired 60,300 new shares on June 25 at $0 cost
These transactions occurred following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. The merger agreement triggered full vesting of Philips' options under the 2022 Equity Incentive Plan.
Post-transactions, Philips directly owns 298,464 shares and indirectly controls 34,654 shares through Whetstone Ventures LLC, where he serves as member manager with shared voting and dispositive power.
Thierry Guillaudeux, Chief Scientific Officer of Kineta, reported multiple securities transactions on June 23-25, 2025:
- Exercised 225,000 stock options at $0.36 per share on June 23
- Disposed of 47,647 shares at $0.26 per share through tax withholding (Form F)
- Received 23,100 new shares on June 25 at $0 cost
These transactions occurred in connection with the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and the merger agreement dated December 11, 2024 (amended May 5, 2025), Guillaudeux's options under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Following all transactions, Guillaudeux directly owns 217,333 shares of common stock.
Kineta Director Raymond J. Bartoszek reported multiple stock transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F)
- Received 6,000 new shares as a grant on June 25
Following these transactions, Bartoszek directly owns 31,000 shares and indirectly controls 1,750,474 additional shares through: RLB Holdings Connecticut LLC (1,748,473 shares), his son (1,001 shares), and daughter (1,000 shares). The stock option exercise was triggered by an Optionholder Treatment Agreement dated June 16, 2025, related to a merger agreement between Kineta and TuHURA Biosciences. The options, granted under the 2022 Equity Incentive Plan, became fully vested on June 23, 2025.